Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With PTR

Efficacy and Safety of Autologous Cryopreserved Platelets in Patients With Platelet Refractoriness

The purpose of this study is to improve the platelet level of PTR patients; Prevent and improve bleeding; Help patients to successfully through the bone marrow suppression period after chemotherapy; Reduce the overall rate of PTR and allo-immunity; Saving platelet resources and reducing blood burden.

Inclusion Criteria:

• Patients with ALL，AML，MDS, CML,CLL that suffered from PTR before, with or without HLA antibodies
• The platelet level >150*10E9/L when considering autologous PLT collection
• Age less than 70 years
• The expected life more than 3 months
• Agree to receive autologous platelet cryopreservation and infusion treatment, and sign the informed consent form

Exclusion Criteria:

• Blast cells are found in peripheral blood or bone marrow
• Patients with bacteremia or sepsis
• Coagulation function abnormality
• Patients who have a history of thrombosis and are receiving anticoagulant treatment
• Severe bleeding within 2 weeks
• Participate in another clinical study within 1 month, and have treatment with potential impact on platelets
• Patients with mental disease